Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Type/Product Area

Terms/Details (Date)


Aegerion
Pharmaceuticals
Inc.*

Pfizer Inc.

They entered cross- licensing deals covering patents related to microsomal triglyceride transfer protein inhibitors

The University of Pennsylvania also was a party to the deal; terms were not disclosed (10/6)

Affymetrix
Inc.
(AFFX)

Wyeth

Deal under which Wyeth extended its access to Affymetrix's GeneChip microarray technology

The deal begun in 1994 was extended a further three years; Wyeth is using the technology in drug discovery and development; terms were not disclosed (10/24)

Alantos
Pharmaceuticals
Holdings Inc.*

Servier (France)

Deal to develop Alantos' ALS 2-0426, an oral inhibitor of DPP-IV, for Type II diabetes; it is in Phase I trials

Servier got rights outside the U.S.; Alantos is eligible to receive upfront and milestone payments of $75M, plus double-digit royalties on resulting sales; Servier also will pay for development through Phase II trials (10/24)

AlphaRx Inc.
(OTC BB:ALRX)

Undisclosed U.S.-based company

AlphaRx will do formulation work on three products from the partner, two of which are on the market

The goal is to improve the products' effectiveness; the partner has a six-month option to license the products; AlphaRx gets an up-front payment, as well as potential milestone and royalty payments (11/7)

Ambrilia
Biopharma Inc.
(Canada; TSX:AMB)

Merck & Co. Inc.

Merck got worldwide rights to Ambrilia's HIV/AIDS protease inhibitor program, including the Phase I product PPL-100

Ambrilia gets $17M up front and is eligible to receive up to $215M more in milestone payments; it also would get royalties on resulting sales (10/12)

Arena
Pharmaceuticals
Inc.
(ARNA)

Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson)

Ortho exercised its option to extend the research term in deal to develop drugs targeting the glucose- ependent insulinotropic receptor

Arena is entitled to $2.4M in research funding under the one-year extension; the lead candidate targeting Type II diabetes is in Phase I trials (9/27)

Asklepios Bio-
pharmaceutical
Inc.*

GlaxoSmithKline plc (UK)

Asklepios got certain rights to recombinant adeno- associated virus vector serotypes under a cross-licensing deal

Asklepios' rights include three orphan indications; neither the technology licensed to GSK nor the monetary terms was disclosed (9/28)

Biogen Idec
Inc.
(BIIB)

UCB SA (Belgium)

Deal to to develop and market UCB's Phase I product CDP323 for multiple sclerosis and other potential indications

UCB gets up-front and milestone payments that could exceed $200M; Biogen also will help fund development; commercialization costs and profits would be shared equally (10/2)

BioSante
Pharmaceuticals
Inc.
(AMEX:BPA)
and Antares
Pharma Inc.
(AMEX:AIS)

Bradley Pharmaceuticals Inc.

Bradley got U.S rights to Bio-E-Gel (transdermal estradiol gel), which is under FDA review for treating hot flashes

BioSante gets $2.625M and Antares $0.875M up front; milestones could push payments to BioSante to more than $40M, and to more than $13M for Antares; they also would get royalties on resulting sales (11/8)

Biotica
Technology
Ltd.*
(UK)

Wyeth Pharmaceuticals

Exclusive deal to develop rapamycin analogues from Biotica that target diseases in multiple therapeutic areas

Biotica gets up-front, research and milestone payments that could reach $195M if multiple products are developed; it also would get royalties on resulting sales (10/5)

Biovitrum AB
(Sweden;
SSE:BVT)

Orchid Chemicals & Pharmaceuticals Ltd. (India)

Deal under which Orchid will provide medicinal chemistry services for Biovitrum

The six-month deal covers certain Biovitrum compounds; the deal could be extended and expanded; terms were not disclosed (10/30)

BrainCells
Inc.*

NV Organon (the Netherlands; unit of Akzo Nobel)

Deal to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline

BrainCells will use its neurogenesis technology in the repositioning effort; terms of the deal were not disclosed (10/23)

Can-Fite
BioPharma Ltd.
(Israel; TEL:CFBI)

Seikagaku Corp. (Japan)

Seikagaku got rights to CF101 in Japan for use in inflammatory indications; the deal does not include ophthalmic indications

Can-Fite gets $3.5M up front, and up to $16M more in milestone payments; it also would get royalties on sales (9/25)

Caprion
Pharmaceuticals
Inc.*
(Canada)

Centocor Inc. (unit of Johnson & Johnson)

Centocor got exclusive rights to a number of protein targets that may have applicability in cancer indications

Caprion is entitled to an up-front payment and license fees, along with potential milestone payments and royalties on any resulting sales (10/11)

Cellzome Inc.*

Novartis AG
(Switzerland)

They extended deal focused on molecular pathways through June 2008; it began in 2004

Cellzome technology is being used to identify targets for several disease areas, and to gauge the effects of Novartis compounds; terms of the deal were not disclosed (10/25)

Cenix
BioScience
GmbH*
(Germany)

Merck KGaA (Germany)

Deal under which Cenix will provide RNAi-based services to assist Merck with target discovery and validation

The deal focuses on oncology, and includes an option to expand to other disease programs; terms were not disclosed (9/27)

Cerexa Inc.*

Meiji Seika Kaisha Ltd. (Japan)

Cerexa got exclusive rights to ME1036, a broad- pectrum antibiotic agent

Initiation of Phase I trials was expected in the first half of 2007; terms of the deal were not disclosed (11/1)

ChemBridge
Research
Laboratories
Inc.*

AstraZeneca plc (UK)

Deal to develop small- molecule libraries for use in drug discovery at AstraZeneca

The multiyear deal also includes ChemBridge Corp.; terms and further details were not disclosed (9/21)

Debiopharm
Group*
(Switzerland)

Cambridge Antibody Technology (unit of AstraZeneca plc; UK)

Exclusive deal to develop and market Debiopharm's SC-1 and derivative products; it is a fully human monoclonal IgM antibody

The Phase I/II product targets gastric carcinoma cells; Debiopharm is entitled to upfront and milestone payments in the deal, as well as royalties on resulting sales (10/16)

D-Pharm Ltd.*
(Israel)

Yungjin Pharmaceutical Co. Ltd. (South Korea)

Yungjin got rights in Korea to the stroke product candidate DP-b99

D-Pharm gets $1M up front, along with potential milestone payments; it also will supply product in exchange for a percentage of the reimbursement price (10/23)

EKR
Therapeutics
Inc.*

Helsinn Healthcare SA (Switzerland)

EKR acquired North American rights to the approved oral gel product Gelclair

The product is used in cancer-related pain associated with oral mucositis/stomatitis; terms of the deal were not disclosed (10/12)

Eurand
International
SpA*
(Italy)

GlaxoSmithKline plc(UK)

Eurand will use its taste- masking and tablet-disintegration technologies to develop a new formulation of an undisclosed GSK product

GSK will fund the work, and Eurand would get royalties on resulting sales; Eurand also has certain commercialization rights to the product outside the U.S. (10/4)

Galapagos NV
(the Netherlands;
Euronext:GLPG)

LEO Pharma A/S (Denmark)

Galapagos will use part of its natural compound library for high-throughput screening of LEO antibacterial compounds

Galapagos gets up to €0.4M in project fees and up to €3M in milestone payments; it also would get royalties on resulting sales (11/1)

GeneGo Inc.*

Merck KGaA (Germany)

Pfizer gained expanded access to the MetaCore systems biology platform

The deal now allows all Merck employees access to the technology in perpetuity; terms were not disclosed (9/26)

Gene Logic
Inc.
(GLGC)

Eli Lilly and Co.

Deal to seek alternative development paths for multiple Lilly drug candidates and an option to license compounds Lilly

The compounds were discontinued for reasons other than safety; Gene Logic is entitled to milestone and royalty payments, does not develop (10/12)

GenOdyssee
SA*
(France)

Baxter International Inc.

GenOdyssee will use its protein and other other technologies in a deal to discover novel blood- clotting factors

Baxter will develop and bring to market any resulting products; terms of the deal were not disclosed (10/23)

GTC
Biotherapeutics
Inc.
(GTCB)

LFB Biotechnologies (subsidiary of LFB SA; France)

Deal to develop recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform

GTC has rights in North America, and LFB in Europe; rights elsewhere are shared, as will be costs and profits; LFB bought about $6M in GTC stock as part of a $25M equity commitment, which would give it a 19.9% stake in GTC (10/2)

ImmunoGen
Inc.
(IMGN)

Sanofi-Aventis Group (France) resulting sales (10/18)

Sanofi got nonexclusive rights to use ImmunoGen's resurfacing technology to humanize antibodies in all indications

Sanofi previously had rights only in cancer applications under a 2003 deal; ImmunoGen gets a $1M license fee, plus milestone payments up to $4.5M, and royalties on any

Indevus Pharmaceuticals
Inc.
(IDEV)

Madaus GmbH (Germany)

Madaus got rights to the overactive bladder product Sanctura SR outside the U.S. except in Canada, Japan, Korea and China

Rights will be shared in the four ex-U.S. countries not covered in the license agreement; Indevus will get royalties and manufacturing fees on sales in Madaus' territories (11/6)

Inovio
Biomedical
Corp.
(AMEX:INO)

Wyeth

Wyeth got nonexclusive rights to use electroporation-based delivery technology with certain therapeutic DNA vaccines

Inovio gets a $4.5M license fee, annual maintenance fees, research support, and up to $60M in clinical and regulatory milestones; it also would supply the devices, and get royalties on resulting sales (11/7)

Inspire
Pharmaceuticals
Inc.
(ISPH)

FAES Farma SA (Spain)

Inspire got U.S. and Canadian rights to bilastine, a Phase III oral antihistamine compound for treating allergic rhinitis

Inspire also got rights to an ocular formulation of the compound in various markets worldwide; FAES gets $7M up front, and up to $82M in milestone payments, as well as royalties of 14% to 16% on resulting sales of the oral product (11/1)

IntegraGen
SA*
(France)

Royal DSM NV (the Netherlands)

Collaboration to develop molecular diagnostic products for personalized health care

IntegraGen gets up-front and license fees, R&D funding and royalties on resulting sales; separately, DSM Venturing invested €2M in IntegraGen (11/6)

Intercell AG
(Austria; VSE:ICLL)

Merck & Co. Inc.

They extended relationship to include development of a prophylactic vaccine against Group A Streptococcus infections

Intercell will provide Merck antigens that have shown preclinical promise; Intercell gets $9.5M up front, and is eligible to receive milestone payments of up to $76M, as well as royalties on resulting sales (10/26)

InterMune
Inc.
(ITMN)

F. Hoffmann- La Roche Ltd. (Switzerland)

Exclusive deal to develop and market products from InterMune's hepatitis C virus protease inhibitor program; they also will work on second- generation compounds

The deal includes lead product ITMN-191, which is nearing Phase I trials; InterMune gets $60M up front and up to $470M in milestones related to ITMN-191; Roche will fund 67% of development costs and would pay royalties on sales; InterMune has a 50-50 commercialization option in the U.S. (10/16)

Isogenica
Ltd.*
(UK)

UCB SA
(Belgium)

Deal to discover novel peptide ligands, which UCB would incorporate into therapeutic products

The focus of the research and license deal is antibiotics; terms of the deal were not disclosed (11/6)

Jennerex
Biotherapeutics
Inc.*

Green Cross Corp. (South Korea)

Green Cross got rights in Korea to JX-594, an oncolytic vaccinia virus

Liver cancer is the initial indication; Green Cross will fund Korean development, and would pay royalties on any resulting sales (10/17)

Keryx Bio-
pharmaceuticals
Inc.
(KERX)

Kyowa Hakko Kogyo Co. Ltd. (Japan)

Keryx got rights outside Japan to UCN-01, a multi-kinase inhibitor in Phase II trials in cancer indications

Kyowa Hakko is entitled to up-front, milestone and royalty payments in the deal (10/4)

LibraGen*
(France)

Sanofi-Aventis Group (France)

Deal to use LibraGen's expertise in microbial biodiversity to discover compounds for treating infectious diseases and cancer

They intend to discover new chemical structures derived from non-cultivable microorganisms; LibraGen is eligible to receive milestone and royalty payments (10/25)

MediciNova
Inc.
(OSE:4875)

Meiji Seika Kaisha Ltd. (Japan)

MediciNova acquired two small- molecule antithrombic agents, MN-447 and MN-462

Rights to the preclinical products are worldwide outside Japan and certain other Asian countries; terms of the deal were not disclosed (11/1)

MedImmune
Inc.
(MEDI)

ZLB Behring (unit of CSL Ltd.; Australia)

ZLB acquired the immuno- globulin product CytoGam, which is marketed for prevention of cytomegalovirus infection

MedImmune gets $50M up front and up to $70M more in sales-based milestones (11/8)

Melior
Discovery Inc.*

Merck & Co. Inc.

Melior will use its in vivo discovery platform to evaluate the activity of certain neuroscience compounds from Merck

Melior gets undisclosed fees for granting Merck priority access to the technology; further terms were not disclosed (11/7)

MSM Protein
Technologies
Inc.*

Cambridge Antibody Technology (unit of Astrazeneca plc; UK)

Collaboration to discover antibody- based drugs targeting multi-spanning membrane proteins

MSM will apply its technologies to antibody libraries from CAT, which will fund the work; both companies could have milestone and royalty obligations on resulting products (10/17)

Nabi Bio-
pharmaceuticals
(NABI)

Fresenius Medical Care AG & Co. KGaA (Germany)

Fresenius is acquiring Nabi's PhosLo (calcium acetate) product and related assets

Nabi will get $65M at closing and up to $20M more in milestone payments, along with royalty payments on a new formulation in development that could push the deal's value to $150M (10/12)

OncoMethylome
Sciences
SA*
(Belgium)

Schering-Plough Corp.

Schering-Plough got rights to use assay technology for measuring the methylation status of the MGMT gene

The effort is focused on optimizing SP's Temodar therapy in patients with glioblastoma multiforme; OncoMethylome gets a license payment, sample-processing fees and potential milestone payments (10/24)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Schering-Plough Corp.

They extended until April 2007 a deal started in 2003 to develop small-molecule therapeutics

Pharmacopeia gets funding for 10 chemistry employees, and remains entitled to milestone and royalty payments on resulting compounds (9/28)

Plexxikon
Inc.*

F. Hoffmann- La Roche Ltd. (Switzerland)

Deal to develop and market PLX4032, Plexxikon's agent targeting a mutated form of the BRAF kinase gene; Phase I trials of the lead compound, PLX4032, are upcoming

Plexxikon gets $40M up front and $6M in research funding over two years; it could receive $660M in development and sales milestones for multiple indications and/or compounds, as well as royalties on sales; it retained a U.S. co-promotion option (10/4)

Plexxikon
Inc.*

Servier (France)

Deal to discover non-peptidic inhibitors of renin, which may be applicable in hypertension, renal failure and vascular disease

Plexxikon gets an up-front payment, research funding and potential milestone payments that together could exceed $100M; Servier gets worldwide rights, and would pay royalties on resulting sales (10/2)

ProStrakan
Group plc
(UK; LSE:PSK)

Novartis AG (Switzerland)

Collaboration to develop antibodies for treating bone-related diseases

ProStrakan gets up-front and R&D payments of $5.75M over two years; it also could earn $140M in development and sales milestones; ProStrakan retained rights to small-molecule approaches (9/27)

Protalix
Biotherapeutics
Ltd.*
(Israel)

Teva Pharmaceutical Industries Ltd. (Israel)

Teva got rights to two proteins, which will be developed using Protalix's plant cell culture platform

Protalix is entitled to milestone and royalty payments in the deal; it also retained certain exclusive manufacturing rights (9/26)

Quark
Biotech Inc.*

Pfizer Inc.

Pfizer got exclusive rights to the RTP- 01 gene, and to molecules that modify its expression or function

RTP-801 is involved in the development of pathologic blood vessels, and is being studied in age-related macular degeneration; terms of the deal were not disclosed; Quark collaborator SR Pharma Ltd. said it was entitled to $2M up front and up to $95M in milestone payments in the deal, as well as royalties on sales (9/26)

Regeneron
Pharmaceuticals
Inc.
(REGN)

Bayer HealthCare (Germany)

Deal to develop and market Regeneron's VEGF Trap technology outside the U.S. for treating eye diseases

Regeneron gets $75M up front and up to $110M in development milestones, as well as $135M in sales milestones; they will share ex-U.S. costs and any profits (10/18)

Santarus Inc.
(SNTS)

Schering-Plough Corp.

Schering-Plough got certain exclusive rights to Zegerid products for the over-the-counter market in the U.S. and Canada

SP will develop and market the 20-mg (lower) dose of omeprazole for heartburn- related indications; Santarus gets $15M up front and up to $65M in regulatory and sales milestones, as well as royalties on sales (10/18)

Sapphire
Therapeutics
Inc.*

Ono Pharmaceutical Co. Ltd. (Japan)

Ono got rights in Japan, Korea and Taiwan to RC-1291, a small- molecule ghrelin mimetic

Sapphire is entitled to up-front, milestone and royalty payments in the deal; RC-1291 is being developed for treating cancer anorexia/cachexia (10/26)

Scolr Pharma Inc. (AMEX:DDD)

Undisclosed U.S.- ased company

Deal to develop an oral form of an antiviral compound being developed against influenza

Scolr will use its CDT drug delivery technology in the effort; research could lead to a license agreement; terms of the deal were not disclosed (9/22)

ThromboGenics
NV
(Belgium;
Euronext:THR)
and Geymonat
SpA*
(Italy)

Roche Diagnostics (Switzerland)

Roche got rights to diagnostic applications of the pro-angiogenic placental growth factor PIGF in vascular disorders

Terms of the worldwide, co-exclusive license agreement were not disclosed (10/19)

TopoTarget
A/S
(Denmark;
CSE:TOPO) and
CuraGen Corp.
(CRGN)

LEO Pharma A/S (Denmark)

LEO got worldwide rights to the preclinical HDAC inhibitor PXD118490 for treating psoriasis and other dermatological disorders

TopoTarget and CuraGen get €2M up front and up to €32M in milestone payments, as well as royalties on any resulting sales; they will equally share any payments from LEO (11/2)

Transition
Therapeutics
Inc.
(Canada;
TSX:TTH)

Elan Corp. plc (Ireland)

Deal to develop and market Transition's Phase I product AZD- 03 for treatment of Alzheimer's disease

Transition gets up-front payments of $15M, and is eligible to receive up to $185M in milestone payments; they will share costs and any profits, with Elan's share currently 70% (9/27)

Warren
Pharmaceuticals
Inc.*

Shire plc (UK)

Shire got rights to tissue protective cytokine (TPC) technology in areas outside the central nervous system

Warren has identified TPCs that are modifications of erythropoietin; terms of Shire's exclusive license were not disclosed (10/3)

ViRexx
Medical Corp.
(Canada; TSX:VIR)

Defiante Farmaceutica Lda and Tecnogen SCpA (units of Sigma-Tau; Italy)

Deal for the manufacturing and distribution of ViRexx's cancer product Ovarex MAb in Europe and the Middle East

Defiante will purchase C$2M ($1.8M) in ViRexx stock and up to to C$4.5M more; ViRexx stands to receive royalties of 25% on sales in Europe and the Middle East (11/6)

Viropro Inc.
(OTC BB:VPRO)

Biochallenge SA (Tunisia)

Biochallenge got rights to four biogeneric products that it would commercialize in Africa, the Middle East and certain other areas

Viropro is eligible to receive $42M in licensing fees, development and technology transfer costs, and royalties on future sales; Viropro also got a 14% interest in the project (11/7)

Xanthus
Pharmaceuticals
Inc.*

Schering AG (Germany)

Xanthus got exclusive rights to oral fludarabine in the U.S.

Schering is entitled to up-front, milestone and royalty payments in the deal; the cancer drug is approved in Europe and Canada (10/3)

Xenon
Pharmaceuticals
Inc.*
(Canada)

Takeda Pharmaceutical Co. Ltd. (Japan)

Takeda got rights in Japan and certain Asian countries to oral formulations of Xenon's preclinical pain drug XEN401

Xenon gets up-front and potential mile- stone payments of up to $75M, as well as royalties on resulting sales; it also gets a $5M equity investment; Takeda also has an option on backup compounds (10/2)

XOMA Ltd.
(XOMA)

Takeda Pharmaceutical Co. Ltd. (Japan)

Deal under which XOMA will discover therapeutic antibodies against multiple targets selected by Takeda

XOMA is entitled to up-front, milestone and R&D payments that together could total $100M; it also would get royalties on any resulting sales (11/2)

Ziopharm
Oncology Inc.
(ZIOP)

Baxter Healthcare Corp.

Ziopharm is acquiring the Phase I cancer agent indibulin (ZIO-301), which targets mitosis

The definitive agreement calls for Baxter to receive an up- front payment; it also is eligible to get milestone and royalty payments (11/6)


Notes:
# The information in the chart does not cover agricultural agreements or those between biotech companies.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OSE = Osaka Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TEL = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange; VSE = Vienna Stock Exchange.

No Comments